Evidence map›Paper›PMID 22302900›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012

Phospho-specific flow: fixating on the target.

Mark Levis

Abstract readComment
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Mark LevisDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA. levisma@jhmi.edu

Funding

Incorporating FLT3 inhibitors into AML treatment regimensR01CA128864 · NCI · JOHNS HOPKINS UNIVERSITY · PI LEVIS, MARK J · 2008 to 2012
$1.7M
NCI NIH HHS R01 CA128864
6 · The paper itself

Abstract

Targeted therapies are all the rage in oncology research these days. The problem remains as to how to confirm that the target is actually being hit in vivo. This report describes the application of phospho-specific flow cytometry to establish in vivo target inhibition in real time.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCytarabineEtoposideFemaleHumansLeukemia, Myeloid, AcuteMaleMitoxantroneRibosomal Protein S6SirolimusTOR Serine-Threonine KinasesCytarabineEtoposideMitoxantroneMTOR protein, humanRibosomal Protein S6SirolimusTOR Serine-Threonine Kinases

Identifiers

PMID22302900
PMCPMC3306466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.